PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34740861-0	2022	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.	osimertinib	57-68	aurora kinase A	Homo sapiens	49-55	
34740861-2	2022	In the phase III, ADAURA study (NCT02511106), osimertinib demonstrated a highly statistically significant improvement in disease-free survival (DFS) in patients with resected stage IB IIIA EGFRm NSCLC.	osimertinib	46-57	aurora kinase A	Homo sapiens	18-24